These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21186970)

  • 21. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents.
    Emslie GJ; Kennard BD; Mayes TL; Nightingale-Teresi J; Carmody T; Hughes CW; Rush AJ; Tao R; Rintelmann JW
    Am J Psychiatry; 2008 Apr; 165(4):459-67. PubMed ID: 18281410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS).
    Kennard B; Silva S; Vitiello B; Curry J; Kratochvil C; Simons A; Hughes J; Feeny N; Weller E; Sweeney M; Reinecke M; Pathak S; Ginsburg G; Emslie G; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1404-11. PubMed ID: 17135985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    March J; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J;
    JAMA; 2004 Aug; 292(7):807-20. PubMed ID: 15315995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS).
    Vitiello B; Rohde P; Silva S; Wells K; Casat C; Waslick B; Simons A; Reinecke M; Weller E; Kratochvil C; Walkup J; Pathak S; Robins M; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1419-26. PubMed ID: 17135987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Fish Oil Monotherapy on Depression and Prefrontal Neurochemistry in Adolescents at High Risk for Bipolar I Disorder: A 12-Week Placebo-Controlled Proton Magnetic Resonance Spectroscopy Trial.
    McNamara RK; Strawn JR; Tallman MJ; Welge JA; Patino LR; Blom TJ; DelBello MP
    J Child Adolesc Psychopharmacol; 2020 Jun; 30(5):293-305. PubMed ID: 32167792
    [No Abstract]   [Full Text] [Related]  

  • 26. Neurocognitive Predictors of Clinical Improvement in Selective Serotonin Reuptake Inhibitor-Treated Adolescents with Major Depressive Disorder.
    Maalouf F; Bakhti R; Tamim H; Shehab S; Brent D
    J Child Adolesc Psychopharmacol; 2018; 28(6):387-394. PubMed ID: 29652529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS).
    Curry J; Rohde P; Simons A; Silva S; Vitiello B; Kratochvil C; Reinecke M; Feeny N; Wells K; Pathak S; Weller E; Rosenberg D; Kennard B; Robins M; Ginsburg G; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1427-39. PubMed ID: 17135988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Relationship Between Plasma Cytokine Levels and Response to Selective Serotonin Reuptake Inhibitor Treatment in Children and Adolescents with Depression and/or Anxiety Disorders.
    Amitai M; Taler M; Carmel M; Michaelovsky E; Eilat T; Yablonski M; Orpaz N; Chen A; Apter A; Weizman A; Fennig S
    J Child Adolesc Psychopharmacol; 2016 Oct; 26(8):727-732. PubMed ID: 26771135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.
    Findling RL; DelBello MP; Zuddas A; Emslie GJ; Ettrup A; Petersen ML; Schmidt SN; Rosen M
    J Am Acad Child Adolesc Psychiatry; 2022 Sep; 61(9):1106-1118.e2. PubMed ID: 35033635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder.
    Judd LL; Rapaport MH; Yonkers KA; Rush AJ; Frank E; Thase ME; Kupfer DJ; Plewes JM; Schettler PJ; Tollefson G
    Am J Psychiatry; 2004 Oct; 161(10):1864-71. PubMed ID: 15465984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder.
    Atkinson S; Lubaczewski S; Ramaker S; England RD; Wajsbrot DB; Abbas R; Findling RL
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):55-65. PubMed ID: 29185786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial.
    Emslie GJ; Heiligenstein JH; Wagner KD; Hoog SL; Ernest DE; Brown E; Nilsson M; Jacobson JG
    J Am Acad Child Adolesc Psychiatry; 2002 Oct; 41(10):1205-15. PubMed ID: 12364842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment-Resistant Depression in Adolescents: Clinical Features and Measurement of Treatment Resistance.
    Strawn JR; Aaronson ST; Elmaadawi AZ; Schrodt GR; Holbert RC; Verdoliva S; Heart K; Demitrack MA; Croarkin PE
    J Child Adolesc Psychopharmacol; 2020 May; 30(4):261-266. PubMed ID: 32315537
    [No Abstract]   [Full Text] [Related]  

  • 34. Anxiety as a predictor of treatment outcome in children and adolescents with depression.
    Cheung A; Mayes T; Levitt A; Schaffer A; Michalak E; Kiss A; Emslie G
    J Child Adolesc Psychopharmacol; 2010 Jun; 20(3):211-6. PubMed ID: 20578934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes.
    Barbosa L; Berk M; Vorster M
    J Clin Psychiatry; 2003 Apr; 64(4):403-7. PubMed ID: 12716240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacotherapy of depressive illness in adolescents: an open-label comparison of fluoxetine with imipramine-treated historical controls.
    Strober M; DeAntonio M; Schmidt-Lackner S; Pataki C; Freeman R; Rigali J; Rao U
    J Clin Psychiatry; 1999 Mar; 60(3):164-9. PubMed ID: 10192591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of extended evaluation on depressive symptoms in children and adolescents.
    Rintelmann JW; Emslie GJ; Rush AJ; Varghese T; Gullion CM; Kowatch RA; Hughes CW
    J Affect Disord; 1996 Nov; 41(2):149-56. PubMed ID: 8961043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of the children's depression rating scale- revised for adolescents in primary-care pediatric use in India.
    Basker MM; Russell PS; Russell S; Moses PD
    Indian J Med Sci; 2010 Feb; 64(2):72-80. PubMed ID: 22466496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
    Wheatley DP; van Moffaert M; Timmerman L; Kremer CM
    J Clin Psychiatry; 1998 Jun; 59(6):306-12. PubMed ID: 9671343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients.
    Sechter D; Troy S; Paternetti S; Boyer P
    Eur Psychiatry; 1999 Mar; 14(1):41-8. PubMed ID: 10572324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.